0.18毫克氟轻松植入剂治疗非感染性葡萄膜炎后高眼压的发生率与管理
本研究回顾性分析275眼接受0.18毫克氟轻松植入剂治疗非感染性葡萄膜炎累及后段的真实世界数据,平均随访20.59个月,高眼压发生率为10.5%。基线眼压较高和使用降眼压药物是眼压升高的最强预测因素,提示该亚组需更密切监测。
要点
- 氟轻松植入剂治疗后高眼压发生率为10.5%,眼压≥30 mmHg者占5.82%。
- 基线眼压每升高1 mmHg,眼压升高风险调整OR为1.41(95%CI 1.19-1.67)。
- 基线使用降眼压药物者眼压升高风险显著增加(OR 8.56,95%CI 2.61-28.11)。
核心结论
- 0.18毫克氟轻松植入剂治疗非感染性葡萄膜炎累及后段与低高眼压发生率相关,支持其安全性。
- 基线眼压较高和既往使用降眼压药物的眼发生高眼压风险显著增加,需更密切监测眼压。
研究设计与样本
- 回顾性研究,纳入2019至2025年接受0.18毫克氟轻松植入剂治疗且随访≥1个月的眼睛。
- 共275眼(178例患者),平均年龄62.87岁,平均随访20.59±0.72个月。
主要发现
- 高眼压(眼压>24 mmHg)发生率为10.5%,眼压≥30 mmHg发生率为5.82%,眼压较基线升高>12 mmHg发生率为7.3%。
- 高眼压眼中,41.4%经观察缓解,44.8%需局部药物治疗(平均1.78种药物),10.3%需切开手术。
- 基线眼压升高(调整OR 1.41每1 mmHg,95%CI 1.19-1.67)和基线使用降眼压药物(OR 8.56,95%CI 2.61-28.11)是眼压升高的最强预测因素。
关键数值与推荐
- 高眼压定义为眼压>24 mmHg。
- 基线时28.4%的眼有青光眼,32.4%有高眼压,38.5%使用降眼压治疗,31.3%需补充皮质类固醇注射。
临床怎么用
- 对基线眼压较高或正在使用降眼压药物的患者,植入后应加强眼压监测。
- 多数高眼压可通过观察或局部降眼压药物管理,少数需手术干预。
局限性
- 回顾性设计可能引入选择偏倚和信息偏倚。
- 随访时间平均约20.59个月,长期安全性数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the real-world incidence and management of ocular hypertension (OHT) following intravitreal 0.18mg fluocinolone acetonide implant (FAi, Yutiq) for non-infectious uveitis affecting the posterior segment (NIU-PS). METHODS: Retrospective review of eyes treated with 0.18 mg FAi (2019-2025) with ≥1 month follow-up. Primary outcome was OHT (IOP >24 mmHg). Secondary outcomes included IOP ≥30 mmHg, >12 mmHg IOP increase from baseline, and OHT treatment. RESULTS: A total of 275 FAi-treated eyes (178 patients, mean age: 62.87 years) were included. Patients received an average of 1.05 FAi (range:1-2), with mean follow-up of 20.59 ± 0.72 months. Mean baseline IOP was 14.30 ± 3.90 mmHg. Glaucoma and OHT were present in 28.4% and 32.4% of eyes, respectively and 38.5% were on IOP-lowering therapy. Supplemental corticosteroid injections were required in 31.3%. The OHT rate after FAi was 10.5%. Elevated IOP ≥30 mmHg occurred in 5.82%. IOP >12 mmHg from baseline occurred in 7.3%. Among OHT eyes, 41.4% resolved with observation, 44.8% required topical therapy (mean 1.78 agents), and 10.3% required incisional surgery. Higher baseline IOP (adjusted OR 1.41 per 1 mmHg increase, 95% CI:1.19-1.67) and baseline IOP-lowering medication use (OR 8.56, 95% CI:2.61-28.11) were the strongest predictors of rise in IOP. CONCLUSION: FAi for the treatment of NIU-PS was associated with low rates of OHT, reinforcing its safety. Eyes with higher baseline IOP and those on prior IOP-lowering medications had a substantially increased risk of OHT, highlighting the need for closer IOP monitoring in this subgroup.
引用
- Farrell LC, Gomes IVY, Zafar S, et al. Incidence and Management of Ocular Hypertension Following the 0.18 mg Fluocinolone Acetonide Implant for Non-infectious Uveitis affecting the Posterior Segment. Retina. 2026. PMID: 42720983. doi:10.1097/IAE.0000000000005012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。